{"entity":{"id":"nct06589440","kind":"trial","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","aka":[],"tldr":"A phase 2 trial of Botensilimab in colorectal cancer, run by Stingray Therapeutics, now recruiting.","summary":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) is a phase 2 interventional study registered as NCT06589440 by Stingray Therapeutics, with 70 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-07-31. Interventions recorded: SR-8541A. Conditions listed: Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06589440","url":"https://clinicaltrials.gov/study/NCT06589440"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["botensilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06589440","phase":"2","setting":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)","sponsor":"Stingray Therapeutics","enrolled":70,"outcomes":[]},"route":"/trials/nct06589440/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/"}]}}